Pathfinders in Biopharma

→ WHAT IT COVERS RBC Capital Markets analyst Brian Abrams assesses biotech's 80% rally from April 2025 lows, evaluating whether sector momentum can persist through 2026 amid rising valuations, regulatory uncertainty, M&A activity, and emerging innovation in obesity, psychedelics, and protein degraders. → KEY INSIGHTS - **Rally positioning:** Biotech is approximately in the "sixth inning" of its current rally, with the XBI still down 17% over five years versus the S&P 500 up 80%, meaning...

→ WHAT IT COVERS MindMed CEO Rob Barrow outlines how the company is advancing LSD-based therapy through three Phase 3 pivotal trials targeting generalized anxiety disorder and major depressive disorder, with readouts expected in 2026 for a potential 50 million patient market. → KEY INSIGHTS - **Indication scope strategy:** Target broad populations rather than niche ones.

→ WHAT IT COVERS EyePoint Pharmaceuticals CFO George Elston outlines the company's DuraView program for wet AMD, its $318M cash runway through 2027, two global Phase 3 trials, and capital allocation strategy at RBC's 2025 Global Healthcare Conference. → KEY INSIGHTS - **DuraView Mechanism Differentiation:** DuraView (vorolanib) introduces the first new mechanism of action in retinal disease in 15–20 years.

→ WHAT IT COVERS Haris Panethopoulos of Blackstone Life Sciences explains how the firm deploys over $10B AUM across three strategies—collaboration funding, asset ownership, and royalty/debt financing—to bridge the R&D funding gap at major biopharma companies, achieving an 85% phase three success rate against the industry's 48% average. → KEY INSIGHTS - **Phase III Selection Discipline:** Blackstone Life Sciences targets registration-enabling studies specifically because they represent the...

→ WHAT IT COVERS Compass Pathways CEO Kabir Nath discusses COMP360, a psilocybin-based treatment for treatment-resistant depression, as the company prepares three phase three trial readouts over the next fifteen to eighteen months, marking the first classic psychedelic to reach this stage. → KEY INSIGHTS - **Phase Three Timeline:** Compass has three sequential phase three readouts scheduled within fifteen to eighteen months: six-week primary endpoint data arriving next month, twenty-six-week...

→ WHAT IT COVERS Cidara Therapeutics CEO Jeff Stein discusses CD388, a single-dose antifungal-to-antiviral platform molecule targeting neuraminidase to deliver universal influenza protection across all strains, including for 50 million immunocompromised Americans who cannot respond to conventional vaccines. → KEY INSIGHTS - **Universal flu protection gap:** Over 50 million high-risk or immunocompromised Americans fail to mount adequate responses to flu vaccines, creating a population entirely...

→ WHAT IT COVERS Ocular Therapeutix CEO Praveen Duggal outlines how the company's lead drug candidate EXPaxley, a tunable dissolvable hydrogel delivering a tyrosine kinase inhibitor, targets two core failures in wet AMD treatment: 40% patient dropout rates and long-term vision loss from fibrosis, with SOL1 trial readout expected Q1 2026. → KEY INSIGHTS - **Patient dropout economics:** 40% of wet AMD patients in the U.S.

→ WHAT IT COVERS PTC Therapeutics CEO Matt Klein outlines how the company leverages RNA splicing and ferroptosis platforms across PKU, Huntington's disease, and Friedreich's ataxia, while targeting cash flow breakeven through strategic partnerships and disciplined capital allocation. → KEY INSIGHTS - **Platform compounding:** Focusing on a single scientific capability — small molecule RNA splicing — across multiple diseases accelerates development timelines.

→ WHAT IT COVERS BioAge CEO Kristen Fortney explains how studying centenarian biology and aging pathways—including NLRP3 inflammation and exercise-mimicking compounds like apelin—drives drug discovery targeting metabolic and age-related diseases. → KEY INSIGHTS - **NLRP3 Inflammasome Targeting:** Chronic inflammation rises with age and drives metabolic disease, including obesity.

→ WHAT IT COVERS RBC Capital Markets' Brian Abrams outlines the 2025 biotech landscape, where unconventional FDA and HHS leadership nominees, $350B in pharma patent cliffs, and AI-driven drug development create simultaneous headwinds and deal-making opportunities. → KEY INSIGHTS - **M&A Opportunity:** Large biopharma faces over $350B in patent-cliff-exposed sales this decade and holds $150B+ in cash reserves.